Wanbury Ltd strengthens Brazil dominance with Sertraline Form II approval, here's what it meansWanbury Ltd strengthens Brazil dominance with Sertraline Form II approval, here's what it means

Introduction

Leading pharmaceutical company received ANVISA Brazil approval for Sertraline Form II and customer approval for special metformin DC grade with potential annual business of ₹15 crore.

Also Read: Happiest Minds shares soar as AI-first strategy boosts FY27 revenue outlook to 12.5%

Share price movement of Wanbury

On March 12, 2026, Wanbury Ltd opened at ₹245.20, down 0.06% from its previous close of ₹245.35. The stock reached a high of ₹256.00 (4.34%) and a low of ₹238.00. By 1:15 PM, it traded at ₹256.00, a 4.34% increase, with a market cap of ₹894.45 crore.

Wanbury Gets Brazil Sertraline Approval

Wanbury Limited said Brazil’s health regulator ANVISA approved Sertraline Form II for the company. Wanbury already holds approval for Sertraline hydrochloride Form I in the Brazilian market.

The company currently holds about 75 percent market share for sertraline in Brazil. The new approval for Sertraline Form II is expected to support further consolidation of its business.

Wanbury Limited also received approval from a major customer for a special DC grade of metformin. The opportunity has potential business of about ₹15 crore per year.

Stock performance of Wanbury for period of 1 week, 6 months, and 1 year

Wanbury Ltd has delivered a 1-week return of -1.96%, a 6-month return of -5.80%, and a 1-year return of 20.3%.

Also Read: 3i Infotech gains 5% after bagging major IT managed services order from leading Indian industrial firm

Shareholding pattern of Wanbury

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	43.10%	39.60%	43.10%
FII	0.70%	0.80%	0.80%
DII	0.00%	0.00%	0.00%
Public	56%	60%	56%

About Wanbury

Wanbury Ltd (NSE: WANBURY) is a pharmaceutical company incorporated in 1988. It operates in pharmaceutical manufacturing, research, and related activities in the healthcare sector.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs